Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2024

Commission File No. 001-39621

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

Level 4

650 Chapel Street

South Yarra, Victoria, 3141

Australia

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

---

 

EXHIBIT INDEX

 

Exhibit		Description
99.1		Press Release - Opthea to Participate in November Investor Conferences

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

	OPTHEA LIMITED
	(Registrant)
	By:	/s/ Frederic Guerard
	Name:	Frederic Guerard
	Title:	Chief Executive Officer

 

Date: 11/04/2024

 

---

Exhibit 99.1

 

ASX, Nasdaq and Media Release

 

November 4, 2024

 

UPDATE -- Opthea to Participate in November Investor Conferences

Virtual Bell Potter Healthcare Conference, November 18, 2024

Jefferies London Healthcare Conference, November 19, 2024

 

Melbourne, Australia, and Princeton, NJ, US, November 4, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.

Conference details are as follows:

Bell Potter Healthcare Conference

Presentation: Monday, November 18, 2024, 3:00 PM AEDT (Virtual)

Presenter: Frederic Guerard, PharmD, CEO, Opthea

The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

Jefferies London Healthcare Conference 2024

One-on-One Meetings: Tuesday, November 19, 2024

Participant: Frederic Guerard, PharmD, CEO, Opthea

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, Pharm D, CEO

 

---

 

 

 

 

Investor Inquiries	Join our email database to receive program updates:
PJ Kelleher LifeSci Advisors LLC Email: [e-mail] Phone: [phone]   Media Inquiries Silvana Guerci-Lena NorthStream Global Partners [e-mail]	Tel: [phone] Email: [e-mail] Web: www.opthea.com             Source: Opthea Limited

 

 

---

---